| 发明名称 |
Antibodies against human angiopoietin 2 |
| 摘要 |
The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2). The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2). |
| 申请公布号 |
US9109027(B2) |
申请公布日期 |
2015.08.18 |
| 申请号 |
US201213548244 |
申请日期 |
2012.07.13 |
| 申请人 |
Hoffman-La Roche Inc. |
发明人 |
Brinkmann Ulrich;Griep Remko Albert;Kaluza Klaus;Kavlie Anita;Klein Christian;Regula Joerg Thomas;Scheuer Werner |
| 分类号 |
A61K39/395;C07K16/22;A61K39/00;C12N15/85 |
主分类号 |
A61K39/395 |
| 代理机构 |
|
代理人 |
Kalinowski Grant |
| 主权项 |
1. A method of treating a retinopathy in a patient comprising administering, to the patient an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises:
(A) a heavy chain variable domain which comprises a CDR3 region of SEQ ID NO: 33, a CDR2 region of SEQ ID NO: 34 and a CDR1 region of SEQ ID NO: 35; and (B) a light chain variable domain which comprises a CDR3 region of SEQ ID NO: 36, a CDR2 region of SEQ ID NO: 37 and a CDR1 region of SEQ ID NO: 38. |
| 地址 |
Little Falls NJ US |
